The second-most significant disease in dairy operations. 6 22% of unweaned heifer deaths 6 46% of weaned heifer deaths 6

Transcription

1 Superior protection right from the start.

2 The costs of respiratory disease are astounding. $1B ANNUAL COST #1 BEEF It has been estimated that BRD costs the cattle industry $1 billion annually from death, reduced feed efficiency and treatment costs. 1 Respiratory disease remains the most economically devastating condition in the beef industry 2 Approximately 75% of feedlot illnesses 3,4,5 50% of feedlot deaths 3,4,5 #2 DAIRY The second-most significant disease in dairy operations. 6 22% of unweaned heifer deaths 6 46% of weaned heifer deaths 6 BRSV IBR PI 3 Prevalence of 41% to 70% in U.S. 7 BRSV infection is associated with high morbidity (60% to 80%) 8 Fatality rates may be as high as 20% 8 Easily spread Causes severe upper respiratory infections Possible latent infection Immunosuppressive May predispose cattle to bacterial pneumonia 9

3 Brsv can be prevented. INFORCE 3 is the first and only respiratory vaccine to be granted the prevention of disease indication, the highest label claim available for BRSV protection. 90% 80% % Mortality 60% 40% 20% 0% 0% 0% 3- to 9-dayold 6- to 8-weekold INFORCE 3 = NO DEATHS All INFORCE 3 vaccinates survived severe BRSV challenges, while almost all unvaccinated controls died. 10,11 (P < ) (P ) INFORCE 3 Control 60% 57.6% % Lung Damage 40% 20% 0% 13.5% 43.8% 3- to 9-dayold 5.8% 6- to 8-weekold INFORCE 3 = LESS LUNG DAMAGE Fewer lung lesions due to BRSV infections mean INFORCE 3 vaccinates should be expected to require reduced labor and treatment costs, and improved productivity. 9,10 (P=0.0006) (P<0.0001) INFORCE 3 Control

4 A strong defense against ibr and pi 3 viruses. 80% % Morbidity 60% 40% 20% 0% 5.6% 5% 3- to 9-dayold 6- to 8-weekold INFORCE 3 = LESS IBR DISEASE Fewer sick calves mean less treatment cost, reduced labor requirements and decreased chance of secondary bacterial infection. 12,13 (P < ) (P < ) INFORCE 3 Control 99.9% LESS VIRUS SHED PI3 INFORCE 3 = LESS PI 3 VIRUS SHEDDING Compared with unvaccinated controls, INFORCE 3 vaccinates shed 99.9% less virus after challenge. 14 Developed specifically for intranasal use. Helps stimulate local immunity Triggers a rapid innate immune response Helps provide protection where viruses attack first Helps prime the immune system for a strong memory response to subsequent disease challenges

5 Safe for use in all types, ages and classes of cattle. The safety of INFORCE 3 was demonstrated in three separate studies. 1. Field safety study 15 : The safety of INFORCE 3 was evaluated in a cattle safety study, which was one of the largest ever conducted by Pfizer Animal Health. INFORCE 3 was administered intranasally to: 0- to 8-day-old calves Weaned calves High-stress stocker cattle Pregnant cows in all three trimesters Total of 1,873 animals Three geographic locations RESULTS INFORCE 3: SAFE IN ALL TYPES, AGES AND CLASSES OF CATTLE 2. Intensive safety study in young calves 16 : INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally: A 10X concentrated dose to 3- to 10-day-old colostrum-deprived calves. A dose of a commercial vaccine was administered parenterally to all animals 14 days post-intranasal dose. RESULTS INFORCE 3: SAFE IN YOUNG CALVES 3. High-risk stocker study 17 : INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally to: High-risk stocker calves on arrival at a feedlot A dose of a commercial vaccine was administered parenterally to all calves 14 days post-intranasal dose RESULTS INFORCE 3: SAFE IN HIGH-RISK STOCKER CATTLE

6 A strong foundation for a complete vaccination protocol. Team up with your veterinarian to develop a complete vaccination protocol, starting with INFORCE 3. INFORCE 3 helps give cattle a stronger start for greater productivity Early protection can help reduce susceptibility to secondary bacterial infections For dairy herds, use INFORCE 3 in baby calves, on arrival, at weaning, before moving to group pens, or with cows and heifers prefreshening INFORCE 3 is perfect for use in calves in beef herds at branding, preconditioning, weaning, pre-shipment or on arrival in stocker or feedlots Get your cattle off to a stronger, healthier start with INFORCE 3. To learn more, contact your Pfizer Animal Health representative, call or visit INFORCE 3 is available in four convenient dose sizes. 1 Brodersen BA, Bovine respiratory syncytial virus. Vet Clin Food Anim 2010;26: NAHMS Beef Cow/Calf Health & Productivity Audit; Part III: Beef Cow/Calf Health Management, January Available at: Accessed July Edwards AJ. Respiratory diseases of feedlot cattle in the USA. Bovine Practitioner 1996;30: Galyean ML, Perino LJ, Duff CG. Interaction of cattle health/immunity and nutrition. J Anim Sci 1999;77: Loneragan DH, Dargatz DA, Morley PS, et al. Trends in mortality rates among cattle in U.S. feedlots. J Amer Vet Med Assoc 2001;219: NAHMS Dairy 2007 Part I: Reference of Dairy Cattle Health and Management Practices in the United States, October Available at: Accessed July Steven T, Grubbs ST, Kania SA, Potgieter LND. Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay. J Vet Diagn Invest 2001;13: Valarcher JF, Geraldine Taylor G. Bovine respiratory syncytial virus infection Vet Res 2007;38: Ellis JA. Bovine parainfluenza-3 virus, Vet Clin Food Anim, 2010 (In press). 10 Data on file, Study Report No. 3131R , Pfizer Inc. 11 Data on file, Study Report No. 3131R , Pfizer Inc. 12 Data on file, Study Report No. 3131R , Pfizer Inc. 13 Data on file, Study Report No. 3131R , Pfizer Inc. 14 Data on file, Study Report No. 3131R , Pfizer Inc. 15 Data on file, Study Report No. 3437R , Pfizer Inc. 16 Data on file, Study Report No. 3131R , Pfizer Inc. 17 Data on file, Study Report No. 3131W , Pfizer Inc. All brands are the property of Pfizer Inc., its affiliates and/or its licensors Pfizer Inc. All rights reserved. INF10006